TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep Ltd ( (AU:IMM) ) has shared an update.
Immutep Ltd has released its annual report for the year ending June 30, 2025, detailing its financial performance and strategic developments. The report highlights the company’s ongoing commitment to advancing its immunotherapy pipeline, which could significantly impact its market position and offer potential benefits to stakeholders in the biotechnology sector.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company is publicly listed on the Australian Securities Exchange and NASDAQ Global Market.
Average Trading Volume: 2,429,062
Technical Sentiment Signal: Buy
Current Market Cap: A$448.9M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.